Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner

Journal of Toxicological Sciences

Volumn 32, Issue 1, 2007, Pages 57-67

  Ogura, Takeharu ^a   Tanaka, Yoshiyuki ^a   Nakata, Tetsushi ^a   Namikawa, Tomoko ^a   Kataoka, Hirofumi ^a   Ohtsubo, Yoshikazu ^a  

^a SAWAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Differentiation; IGF 1 signaling; Myoblasts; Simvastatin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; MESSENGER RNA; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 3; SIMVASTATIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; MUSCLE DEVELOPMENT; MUSCLE WEAKNESS; MYALGIA; MYOBLAST; MYOPATHY; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ANIMALS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN-LIKE GROWTH FACTOR I; MICE; MUSCLE DEVELOPMENT; MYOBLASTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, IGF TYPE 1; SIMVASTATIN;

EID: 33847412697     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.57     Document Type: Article

References (45)

1. Ajenjo, N., Canon, E., Sanchez-Perez, I., Matallanas, D., Leon, J., Perona, R. and Crespo, P. (2004): Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. J. Biol. Chem., 279, 32813-32823.
2. Allal, C., Favre, G., Couderc, B., Salicio, S., Sixou, S., Hamilton, A.D., Sebti, S.M., Lajoie-Mazenc, I. and Pradines, A. (2000): RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J. Biol. Chem., 275, 31001-31008.
3. Bark, T.H., McNurlan, M.A., Lang, C.H. and Garlick, P.J. (1998): Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am. J. Physiol., 275, E118-123.
4. Barton, E.R., Morris, L., Musaro, A., Rosenthal, N. and Sweeney, H.L. (2002): Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell. Biol., 157, 137-148.
5. Bennett, A.M. and Tonks, N.K. (1997): Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science, 278, 1288-1291.
6. Berendse, M., Grounds, M.D. and Lloyd, C.M. (2003): Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp. Cell Res., 291, 435-450.
7. Carlberg, M., Dricu, A., Blegen, H., Wang, M., Hjertman, M., Zickert, P., Hoog, A. and Larsson, O. (1996): Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl- coenzyme a reductase and cell growth. J. Biol. Chem., 271, 17453-17462.
8. Carvalho, A.A., Lima, U.W. and Valiente, R.A. (2004): Statin and fibrate associated myopathy: Study of eight patients. Arq. Neuropsiquiatr., 62, 257-261.
9. Charge, S.B. and Rudnicki, M.A. (2004): Cellular and molecular regulation of muscle regeneration. Physiol. Rev., 84, 209-238.
10. Chen, J.C. and Goldhamer, D.J. (2003): Skeletal muscle stem cells. Reprod. Biol. Endocrinol., 1, 101.
11. Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A. and Landreth, G. (2005): Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem., 280, 34202-34209.
12. Corsini, A., Bellosta, S. and Davidson, M.H. (2005): Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol., 96, 44K-49K.
13. Denoyelle, C., Vasse, M., Korner, M., Mishal, Z., Ganne, F., Vannier, J.P., Soria, J. and Soria, C. (2001): Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis, 22, 1139-1148.
14. Dunnett, C.W. (1955): A multiple procedure for comparing several treatments with a control. J. Am. Stat. Assoc., 50, 1096-1121.
15. Flint, O.P., Masters, B.A., Gregg, R.E. and Durham, S.K. (1997): HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol. Appl. Pharmacol., 145, 99-110.
16. Galvin, C.D., Hardiman, O. and Nolan, C.M. (2003): IGF-1 receptor mediates differentiation of primary cultures of mouse skeletal myoblasts. Mol. Cell Endocrinol., 200, 19-29.
17. Guijarro, C., Blanco-Colio, L.M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J.J., Diaz, C., Hernandez, G. and Egido, J. (1998): 3-Hydroxy-3- methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res., 83, 490-500.
18. Gunning, P., Hardeman, E., Wade, R., Ponte, P., Bains, W., Blau, H.M. and Kedes, L. (1987): Differential patterns of transcript accumulation during human myogenesis. Mol. Cell Biol., 7, 4100-4114.
19. Hansen, K.E., Hildebrand, J.P., Ferguson, E.E. and Stein, J.H. (2005): Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med., 165, 2671-2676.
20. Ikeuchi, H., Kuroiwa, T., Yamashita, S., Hiramatsu, N., Maeshima, A., Kaneko, Y., Hiromura, K., Ueki, K. and Nojima, Y. (2004): Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: Therapeutic implications for tubulointerstitial fibrosis. Nephron. Exp. Nephrol., 97, e115-122.
21. Jones, N.C., Fedorov, Y.V., Rosenthal, R.S. and Olwin, B.B. (2001): ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion J. Cell. Physiol., 186, 104-115.
22. Lee, J., Lee, I., Park, C. and Kang, W.K. (2006): Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem. Biophys. Res. Commun., 339, 748-754.
23. Machida, S. and Booth, F.W. (2004): Insulin-like growth factor 1 and muscle growth: Implication for satellite cell proliferation. Proc. Nutr. Soc., 63, 337-340.
24. Mackay, D.J. and Hall, A. (1998): Rho GTPases. J. Biol. Chem., 273, 20685-20688.
25. Mutoh, T., Kumano, T., Nakagawa, H. and Kuriyama, M. (1999): Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett., 444, 85-89.
26. Prendergast, G.C. and Oliff, A. (2000): Farnesyltransferase inhibitors: Antineoplastic properties, mechanisms of action, and clinical prospects. Semin. Cancer. Biol., 10, 443-452.
27. Ridley, A.J. (2001a): Rho GTPases and cell migration. J. Cell Sci., 114, 2713-2722.
28. Ridley, A.J. (2001b): Rho proteins: Linking signaling with membrane trafficking. Traffic., 2, 303-310.
29. Rombouts, K., Kisanga, E., Hellemans, K., Wielant, A., Schuppan, D. and Geerts, A. (2003): Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J. Hepatol., 38, 564-572.
30. Rommel, C., Clarke, B. A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D. and Glass, D.J. (1999): Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286, 1738-1741.
31. Sarker, K.P. and Lee, K.Y. (2004): L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway. Oncogene, 23, 6064-6070.
32. Schultz, E. and McCormick, K.M. (1994): Skeletal muscle satellite cells. Rev. Physiol. Biochem. Pharmacol., 123, 213-257.
33. Seale, P., Asakura, A. and Rudnicki, M.A. (2001): The potential of muscle stem cells. Dev. Cell, 1, 333-342.
34. Seeger, H., Wallwiener, D. and Mueck, A.O. (2003): Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes, 111, 47-48.
35. Shek, A. and Ferrill, M.J. (2001): Statin-fibrate combination therapy. Ann. Pharmacother., 35, 908-917.
36. Silva, M.A., Swanson, A.C., Gandhi, P.J. and Tataronis, G.R. (2006): Statin-related adverse events: A meta-analysis. Clin. Ther., 28, 26-35.
37. Spangenburg, E.E., Bowles, D.K. and Booth, F.W. (2004): Insulin-like growth factor-induced transcriptional activity of the skeletal alpha-actin gene is regulated by signaling mechanisms linked to voltage-gated calcium channels during myoblast differentiation. Endocrinology, 145, 2054-2063.
38. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E. and Fruchart, J.C. (1998): Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98, 2088-2093.
39. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003): Statin-associated myopathy. JAMA., 289, 1681-1690.
40. Tortorella, L.L., Milasincic, D.J. and Pilch, P.F. (2001): Critical proliferation-independent window for basic fibroblast growth factor repression of myogenesis via the p42/p44 MAPK signaling pathway. J. Biol. Chem., 276, 13709-13717.
41. van de Donk, N.W., Lokhorst, H.M., Nijhuis, E.H., Kamphuis, M.M. and Bloem, A.C. (2005): Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin. Cancer. Res., 11, 429-439.
42. Veerkamp, J.H., Smit, J.W., Benders, A.A. and Oosterhof, A. (1996): Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim. Biophys. Acta, 1315, 217-222.
43. Yaffe, D. and Saxel, O. (1977): Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, 270, 725-727.
44. Yamakawa, T., Tanaka, S., Kamei, J., Kadonosono, K. and Okuda, K. (2003): Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J. Atheroscler. Thromb., 10, 37-42.
45. Zong, C.S., Chan, J., Levy, D.E., Horvath, C., Sadowski, H.B. and Wang, L.H. (2000): Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem., 275, 15099-15105.